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A B S T R A C T
Based upon an individual’s molecular make-up, personalized molecular medicine provides information regarding
the origin of disease, its treatment and progression, while personalized molecular pharmacology advises on drug pre-
scription and patient response to it, thus ensuring drug effectiveness and preventing drug toxicity or lack of response.
Interindividual differences in drug responses are mostly due to structural variation in parts of genome, e.g. in genes par-
ticipating in drug metabolism, transport or targeting. However, a wide variety of diseases and accompanying health con-
ditions, including patient’s therapy or drug response, also have epigenetic or epigenomic etiology. High priority for per-
sonalized oncologic research stems from inter/intraindividual tumor heterogeneity provoked by gradual acquisition of
multiple random, or programmed mutations and rearrangements as well as epigenetic alterations or by stochastic fluc-
tuations in cell components, all in tight feedback interaction with tumor’s environmental or therapy conditions. Natural
selection subsequently shapes inter/intraindividual tumor heterogeneity by promoting clonal expansion of cells that have
acquired advantageous mutations for tumor population. Hence, the main rationale of personalized molecular oncology
should focus on treating disease by relying on relevant structure and state of patient’s whole molecular network (ge-
nome/transcriptome/RNome/proteome/metabolome/metabonome) in interaction with its unique environmental condi-
tions, thus implying right therapy for the right patient at the right dose and time. The future of personalized oncology
should therefore rely on the methods of systems biology applied in cytology and pathology in order to develop and utilize
the efficient and effective diagnostic, prognostic and predictive biomarkers, consequently providing the molecular infor-
mation on tumor origin, its potential for metastasis, adequate therapy, tumor specific therapy responsiveness, and the
probability of its recurrence.
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Introduction
Personalized medicine implies preventing, diagnosing
and treating disease in each patient on the basis of an in-
dividual’s biology and respective disease pathology. Per-
sonalized medical treatment is concerned with therapy
safety and efficacy as well as with optimized nutrition re-
gimes and lifestyle management and it is tailored consid-
ering patient’s unique clinical data such as family his-
tory, demographic, and environmental factors, all relying
on patient’s unique molecular network make-up. Hence,
variability in interpopulation or interindividual disease
susceptibility and progression as well as in individual’s
therapy response may depend on respective genome/
transcriptome/RNome/proteome/lipidome/metabolome/
metabonome state and structure.
There are several types of structural variations in hu-
man genome: large-scale genomic variation ascribed to
differences in copy numbers, covering about 20 percent
of the length of the human genome; small-scale variation
caused by a difference in one out of about 500 nucleotides
between the genomes of two randomly selected individu-
als, or 6 million single nucleotide polymorphisms (SNPs);
and variants in simple sequence repeats, in larger seg-
mental duplications and in sequences containing trans-
posable elements, all together accounting for about 60%
of the length of the human genome1. In addition, varia-
tions of human molecular networks might be attributed
to the activity of epigenetic mechanisms such as DNA
methylation; acetylation, phosphorylation, ubiquityla-
tion, and sumoylation of histones; protein degradation;
alternations in RNA transcription, RNA splicing, RNA
interference (e.g. in miRNAs expression or siRNA pro-
duction), RNA stability and transposone and viral activ-
763
Received for publication November 17, 2009
ity. Such a plethora of human molecular variations
points to the significant plasticity due to molecular net-
work instability induced also by environmental or di-
etary conditions and cell to cell and cell to matrix interac-
tions, and fixed by evolutionary selection pressure.
In the area of drug response, personalized molecular
medicine overlaps with personalized molecular pharma-
cology, the field studying how individual molecular net-
works or their parts affect drug response and how drug af-
fects individual’s molecular networks2. For example,
personal pharmacogenomics studies the effects of an indi-
vidual genome or it parts (e.g. specific mutations in genes
encoding drug metabolizing, drug transporting, or drug
targeting enzymes) on efficiency and safety of drugs. It
also studies the side-effects of a drug on the respective ge-
nome and its derivatives. Hence, pharmacogenomic evalu-
ation may improve patient’s lifestyle, save both life and
unnecessary expenses and prevent adverse drug reactions
by prescribing selected drugs and determining their pre-
cise dosing, while avoiding lack of drug response. Person-
alized medicine thus relies on translating the science of
molecular pharmacology, limited by complexity of disease
processes and drug therapies, into clinical practice.
Malignant neoplasms are the leading cause of death
among men and women under 85 years of age in the
United States3. Oncogenesis is initiated and promoted or
simply accompanied by the accumulation of numerous
random or programmed somatic mutations or rearrange-
ments and epigenetic alterations, which might be trig-
gered by proficient or irregular intracellular molecular
maintenance systems or left unrepaired due to their inef-
ficiency. Both kinds of multiple and sequential alter-
ations responsible for oncogenesis, i.e. those occurring in
tumor oncogenes and those in tumor suppressor genes,
may be provoked and acted upon by environmental con-
ditions and interactions (e.g. carcinogenic agents and
cell-cell or cell-matrix interactions) or may arise from
and be driven by stochastic fluctuations in configuration,
expression (e.g. gene and protein expression) and in
other epigenomic states of intracellular molecular net-
works. In the process of carcinogenesis, there are two
classes of molecular alterations, the »driver« class that
confers growth advantages of the respective tumor cells
(e.g. mutations occurring in »driver genes«), while the
»passenger« class of alterations occurring in tumor cells,
is considered neutral to the cancer cell fitness. Oncology
research is focused on discerning between these two
classes of alterations. However, since tumor cell popula-
tion is a dynamic structure constantly under selection
pressure, these two classes of alterations might be the
subject of sequential, temporal and spacial changes re-
sulting in tumor interindividual and intraindividual het-
erogeneity.
Standard tumor diagnostic procedures are currently
based on a combination of morphological and immuno-
cytological or immunohistological methods closely con-
nected to clinical data. This strategy, in most cases, pro-
vides sound information on tumor tissue origin, tumor
type, stage and grade as well as on the surgery success of
tumor removal. However, personalized molecular oncol-
ogy should be growingly applied in cancer diagnosis,
prognosis and treatment due to disease complexity aris-
ing from interindividual and intraindividual tumor het-
erogeneity, both depending on intricate feedback rela-
tionships among tumor’s somatic alterations, individual
molecular network maintenance systems, stochastic fluc-
tuations in cellular components, tumor’s environmental
conditions, and on degree and type of mutagenic and
cancerogenic exposure and susceptibility to it, all acted
upon and shaped by evolutionary selective pressure.
Rationale of Personalized Molecular
Oncology
Interindividual tumor heterogeneity
Interestingly, although pancreatic cancers contain an
average of 63 gene alterations (considering only point
mutations, deletions and amplifications in protein-cod-
ing regions) only 12 cellular signaling pathways were
shown to be genetically altered in 67–100% of 24 pancre-
atic cancers surveyed4, hence those alterations appear to
occur in a limited number of »driver pathways«, i.e. the
signaling pathways. However, the pathway components,
i.e. specific genes containing the alterations, are largely
different in each individual tumor4. Breast and colorectal
cancers contain respectively a median of 84 and 76 pro-
tein-coding genes altered by point nonsilent mutation,
and a median of 24 and 9 protein-coding genes altered by
copy number changes5,6 with the number of potential
driver mutations per tumor averaging 157. Only 25 out of
40 putative cancer genes among the alterations discov-
ered in the total of 11 colorectal and 11 breast cancers
and chosen to be reanalyzed further in 96 patients with
colorectal cancers, were found to be mutated in one or
more of those patients, while majority of those 25 genes
were mutated in 5% or fewer of the patients7, meaning
that a large number of mutated cancer driver genes oc-
cur very rarely. In addition, studying exons and splice
junctions of 518 protein kinase genes (the most com-
monly found genes among known cancer genes) in 210
diverse human cancer types, the total of 921 different
base substitutions was revealed, out of which 158 were
expected to be drivers, placed in the total of 119 genes,
and confined to only 66 cancer samples8.
Hence, pathway components altered in any individual
tumor (e.g. by gene mutations) vary widely among indi-
viduals, as well as the sites and types of their alterations
(e.g. type of somatic mutation). Identical alterations may
lead to different clinical manifestations in different indi-
viduals, contributing to tumor heterogeneity and result-
ing in variation in diagnosis, prognosis, potential treat-




As for intraindividual tumor heterogeneity, widely
confirmed in cancer research9, it contributes further to
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the cancer complexity. Primary tumor tissue should be
continuously scrutinized due to incidental acquirement
of additional molecular alterations also provoked by sto-
chastic intracellular fluctuations or by stressful tumor
environmental conditions. Some tumor-acquired alter-
ations might be transient in nature and provoked by
stressful conditions imposed by drug therapy. For exam-
ple, tumor cells from non-small cell lung cancer succeed
to survive due to transient »drug-tolerant« state devel-
oped during drug infliction, while after being devoid of
drug for some time, tumor cell population reverts to
»drug-sensitive« state10,11. Such reversible »drug-toler-
ant« state has been developed by subpopulation of cells
as a response to a lethal drug exposure12. On the other
hand, advantageous proliferation of cells containing heri-
table mutation(s) responsible for therapy resistance
should be predicted by detecting the cell or subpopu-
lation carrying respective mutation. It is therefore obvi-
ous that both heritable and transient therapy-resistance
states should be the subject of diagnostic personalized
molecular oncology.
In addition to primary tumors, both disseminated and
metastatic tumor cells may also possess the clonal heter-
ogeneity character either in comparison to primary tu-
mor13,14 or between themselves. Individual cells from
breast cancer patient showed different abilities to me-
tastasize specific organs of immundeficient mice depend-
ing on molecular signatures of respective cancer cell15.
Potentially metastatic cells primarily infiltrate different
organs (via systemic circulation), but not necessarily all
of them colonize respective organs, which depends on the
set of acquired molecular alterations (mainly in genes en-
coding proteins that influence the interaction of tumor
cells with the invaded microenvironment16) as well as on
the microenvironmental conditions17. The difference be-
tween tumor suppressor and metastasis suppressor ge-
nes was documented with special emphasis on metastatic
colonization suppressors18.
Premalignant cells may disseminate during the early
stages of tumor progression19 and subsequently may ac-
quire alterations in the invaded tissue20, resulting in
even greater tumor clonal heterogeneity. Evidences of
parallel clonal evolution of primary and metastatic tu-
mor population stem from the existence of metastatic tu-
mors with unknown primary origin, which constitute a
significant fraction of clinical cases.
Hence, intraindividual tumor heterogeneity detection
requires personalized molecular oncology to be applied
not only to tumor of an individual but also to its specific
subpopulations in specific microenvironments and at
specific tumor stages. Again, this places special emphasis
on sensitive diagnostic and prognostic methods provided
by molecular oncology21.
Cancer Treatment and Prognosis
Based on detection of tumor inter/intraindividual het-
erogeneity and on deduced respective diagnosis, person-
alized oncology should deal with cancer prognosis and
adequate individually tailored cancer therapy. The re-
search of personalized molecular oncology should there-
fore be performed on the following topics: individual can-
cer risk assessment and susceptibility based on individ-
ual germ line molecular information; type and extent of
individual exposure to mutagens, carcinogens or other
environmental agents; impact of respective exposure on
individual molecular network state and structure; indi-
vidual susceptibility to primary and metastatic tumors
upon exposure to environmental agents; and individual
repair potential of cellular maintenance systems deduced
from their state and structure. The above information
could be obtained from the analysis of individual molecu-
lar network signatures, which should be compared to
well documented and established database of different
types of molecular network signatures either from cells
belonging to the carcinogen-exposed persons or from tu-
mor cells belonging to individuals that developed differ-
ent classes of cancer type and subtype. Both molecular
data (on carcinogen-exposed individual and on cancer pa-
tient) should be accompanied by detailed clinical infor-
mation on respective individuals. Hence, molecular net-
work signatures (e.g. spectra of somatic mutations) can
yield insights into potential carcinogens and other envi-
ronmental exposures as well as on the potential of the
host cell maintenance (repair) systems.
Therapy responsiveness relies on molecular make-up,
microenvironmental conditions of the patient’s tumor
and other cells interacting with tumor, all three compo-
nents being unique for each individual. Hence, different
therapies may need to be tailored for the primary tumor,
disseminating seed and the evolving metastatic subpo-
pulation of the same individual. It is important to deter-
mine not only the type of subpopulation alterations but
also the frequency of cells in respective heterogeneous
subpopulation, if one wants the personal cancer therapy
to be efficiently tailored (e.g. in relation to the extent of
drug sensitivity and patient’s response to it). In this pro-
cess tumor development and putative therapy response
should be predicted on the basis of early tumor analysis.
Drug responsiveness depends on subpopulation’s or
individual’s molecular germline polymorphisms. An ex-
ample of variation in drug targets directly influencing
drug response is represented by thymidylate synthase
(TYMS) over expressed gene variant that is responsible
for poorer survival of respective patient carriers (that
have developed metastasis) due to increased resistance to
5-fluorouracil, inhibitor of TYMS22. On the other hand,
an example of variation in drug metabolizing enzyme in-
directly influencing drug response is represented by the
existence of over 40 different polymorphic types of dihy-
dropyrimidine dehydrogenase (DPYD) that metabolize
5-fluorouracil (implicated in treatment of colon cancer)
into its inactive form23. Hence, decreased DPYD activity
can lead to the accumulation of 5-fluorouracil resulting
in severe toxicities24.
It should be noted that pharmaceutical drugs includ-
ing chemotherapy induce persistent epigenetic changes,
resulting in adverse drug side-effects25 that might de-
S. [tambuk et al.: Personalized Molecular Oncology, Coll. Antropol. 34 (2010) 2: 763–769
765
pend on patient’s susceptibility and hence, should also be
the subject of personalized oncology. In addition, side-ef-
fects might impact on parts of genome implicated in
tumorigenesis (e.g. hypermethylation inflicted by tumor
therapy may contribute in silencing of tumor suppres-
sors genes), thus requiring continuous personalized can-
cer therapy surveillance.
It has been shown that three of the common chemo-
therapeutic agents applied to culture cells are more toxic
to healthy progenitor brain cells than to the cancer cell
lines they intended to treat26. Side effects of chemo-
therapeutics also include increased incidence of cancers
secondary to those being treated27. Hence, cancer ther-
apy should aim for targeted treatment based on personal
oncology that treats the cancer tissue by evading detri-
mental effects on healthy tissue28, all depending on indi-
vidual molecular network signatures of both tumor and
healthy tissue.
As for different potential of cancer recurrence, the
rare intracellular alterations that confer a competitive
advantage may take a long time to achieve clonal domi-
nance. This process depends on the colonization poten-
tial in the respective tumor invaded sites, also requiring
personal molecular oncology approach.
Molecular Systems Biology in Oncology
It is now an accepted fact that origin and progression
of complex diseases, such as cancer, are caused by com-
bined actions of individual’s multiple genes or proteins
or metabolic pathways interacting with environmental
factors and an individual’s lifestyle. Hence, the future of
personalized molecular medicine including personalized
cancer prediction, treatment and prognosis undoubtedly
lies in systems biology. This biology is based on the analy-
sis of integrated action of regulatory networks at many
levels of biological organization, from subcellular level
through cell, tissue, and organ, up to the whole orga-
nism29. Different tools of molecular medicine range from
evaluation of interindividual differences in single genes
(i.e. gene sequencing, genotyping and detection of gene
methylation) to the whole-genome sequencing and appli-
cation of microarrays, i.e. simple collections of individual
probes, that might determine DNA structure and its
copy number; protein structure and its interaction with
other macromolecules, as well as the expression of entire
sets of genes, small non-coding RNAs, proteins, lipids
and metabolic pathways30. Molecular systems biology as
applied in oncology thus implies different -OMIC meth-
ods such as genomics, transcriptomics, proteomics, or
metabolomics/nomics serving in tumor diagnosis and
classification as well as in malignant disease prognosis
and treatment. For example, functional genomics goes
beyond identification of variants and regions associated
with tumor phenotypes; it involves the analysis of the
whole of genome network31.
For the time being sequencing is the primary tool for
cancer genome exploration, since in order to design and
construct microarrays for genomic research one should
sequence and target alteration (e.g. mutation) repertoire
participating in tumor origin and development. For ex-
ample, in comparative genomic hybridization method,
DNA from tumor and respective normal cells is differen-
tially labeled with fluorescent probes and hybridized to
genomic oligonucleotide microarrays, e.g. to SNP (single
nucleotide polymorphism) array that may provide the in-
formation on genome variations with resolution differ-
ence up to the single nucleotide; on the copy number
variations and on loss of heterozygosity32. In order to
synthesize SNP array one should know the whole reper-
toire of variants appearing in respective cancer that is
under analysis. Such information could be provided by
deep sequencing of the many different cases of the re-
spective cancer.
High-throughput sequencing may focus on exome
capturing by array hybridization and further sequencing
on a parallel sequencing platform33,34. The whole exome
sequencing aims to detect cancer specific mutations in
genes belonging to pathway candidates for therapeutic
activity. However, out of 22,910 point mutations discov-
ered by sequencing of lung cancer cell line that has been
exposed to tobacco smoking, only 134 were in protein-co-
ding regions35 which implies necessity to supplement the
mutation spectra of exon sequences by the rest of the ge-
nome. The first comprehensive catalogue of somatic mu-
tations from an individual human cancer genome is com-
pleted on the basis of sequencing the genomes of a
malignant melanoma and a lymphoblastoid cell line from
the same person (COLO-829)36. However, the compari-
son should be extended to germ line molecular make-up
in order to distinguish somatic mutation potentially in-
volved in tumorigenesis and carcinogenesis. Further-
more, considering lowering of the whole-genome sequen-
cing expenses, the sequencing of all tumor stages should
begin to be implemented. By using massively parallel se-
quencing technology and applying it to small-cell lung
cancer cell line, molecular signatures of tobacco exposure
were revealed (pointing on the specific carcinogens pres-
ent in cigarette smoke) together with molecular signa-
tures of DNA repair systems35 of the respective small-cell
lung cancer cell line. Importantly, the ability of sequenc-
ing mixtures of cells with high sensitivity by catching the
information from the single cell among tumor cell popu-
lation, offers a possibility of increasing our knowledge of
malignant lesions in situ, in that way obviating the need
for tissue microdissection.
Another whole genome study i.e. flow cytometry anal-
ysis (FACS) may revel ploidy status of the cell and may
single out cells instead of microdissection method. In
gene expression profiling by using cDNA arrays for anal-
ysis of transcription of thousands of genes or the entire
transcriptome, information is provided on amplification
or reduction of expression of genes of interest. One of the
first classifications of human cancer on the basis of gene
expression profiles was successfully performed for dif-
fuse large B-cell lymphoma37. For example, breast cancer
may be profiled into four distinct molecular subtypes by
applying gene expression arrays38 that are even commer-
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cially available as prognostic markers. Another more in-
formative and sensitive method of quantifying and, in
addition, mapping transcriptomes (i.e. discovering new
exons or genes) is performed by direct ultra-high-throu-
ghput sequencing of cDNA, referred to as RNA-Seq39. On
the other hand, in exploration of detection of DNA me-
thylation (i.e. widespread epigenetic modification), a no-
vel method based on polymerase-incorporated fluore-
scently labeled nucleotides promises to lower the time
and expenses of bisulphite conversion-based sequencing40.
Next step in personalized oncology research should
integrate information obtained from the full cataloguing
of somatic mutation with expression and epigenetic pro-
files of the same cancer cases and should be correlated
with clinical features. In that way, classification of tumor
and early prediction of drug action in tissue would be en-
abled by performing microarray analysis.
However, DNA and gene expression arrays may pro-
vide only limited data on molecular network state and
structure due to epigenetic alterations including post-
-translational protein modifications. Cellular internal
and environmental factors as well as communication and
interaction among cells can alter the activity level or
function of a protein. Protein-protein interactions, post-
-translational modifications and interaction between
protein and DNA, RNA or other macromolecules can all
shift the activity of a protein from what would have been
predicted by its level of transcription. Proteomics tools41
are based on high-performance combinations of chroma-
tography and mass spectrometry. The study of proteo-
mics can generally be divided into two categories: charac-
terization of protein expression and characterization of
protein function. Expression proteomics evaluates the
cellular production of proteins and exploits the differen-
tial expression and post-translational modifications of
proteins between healthy and diseased states. Functional
proteomics, on the other hand, studies the interaction of
proteins to determine how the given protein accom-
plishes its specific cellular task. By detecting the func-
tion of aberrant or over expressed proteins one can tar-
get cancer therapy. In addition, functional proteomics
explores the response of proteins to molecular targeted
therapy in order to determine the efficiency of the tar-
geted therapy. Mapping of protein-protein interactions
can be useful for detecting new proteins that are involved
in cancer as well as novel oncogens, or can provide evi-
dence of common downstream events shared by two dis-
tinct signaling networks aiming to develop therapeutics
directed against these pathway targets.
Proteomic profiling with protein microarrays42 has
been applied in order to determine levels and activation
states of key signaling proteins with the aim of reclassify-
ing human tumors. Protein microarray is a series of im-
mobilized spots, each containing a bait molecule such as
an antibody, a nucleic acid, a drug, or a recombinant pro-
tein or peptide, to which the patient’s tissue or fluid is
applied. If proteins from the sample bind to the bait mol-
ecule, they may be detected using antibody probes. Re-
verse-phase protein microarrays, in which the patient’s
sample is fixed to the slide, and the probe is applied to
the microarray, have demonstrated improved reprodu-
cibility and analytical sensitivity vs. conventional protein
and DNA microarrays. Recent advances in proteomics
research of cancer are described in review43.
Metabolomics analysis provides quantitative descrip-
tion of all low-molecular-weight components of endoge-
nous metabolites in a specified biological sample, charac-
terized by species-specific environmental and physio-
logical conditions. In addition to using chromatography
and mass spectrometry, metabolomics is also taking ad-
vantage of nuclear magnetic resonance to analyze com-
plex sets of metabolites in body fluids including urine,
plasma and tissues in order to reflect biochemical pro-
files of the whole organism (host genetic factors) and re-
gulation of functions that reflect normal and disease
states, as well as to study interactions with the gut mi-
crobial flora and environment factors. By profiling the
metabolomic alterations of prostate cancer progression
sarcosine was suggested as a potential biomarker while
the members of sarcosine metabolic pathway as a poten-
tial therapeutic targets44. Science of metabonomics, on
the other hand, deals with understanding metabolic
changes of a complete system that are caused by interac-
tions, e.g. gene-environment interactions in their broad-
est sense or extended genome and parasitic interactions.
Availability of increasingly powerful high-throughput
technologies, computational tools and integrated knowl-
edge bases, has provided a possibility of establishing new
links among genes/proteins, their biological functions
and a wide range of human diseases, thus providing mo-
lecular description of tumor pathophysiology.
The resected and fine needle-aspirated tissue is the
major determinant of all downstream therapy in molecu-
lar medicine45. On the contrary, culturing the cells may
lead to preferential outgrowth of selected tumor cell
subpopulations, thus changing the representation of the
original tumor. However, iatrogenic variables such as
surgical manipulation, intraoperative drug delivery, and
pathological handling of molecular profile providers that
reflect the biology of the resected tissue, are important
factors in preservation of tissue integrity and quality of
molecular networks45. Postoperative tissue ischemia
time, for example, has been shown to alter gene and pro-
tein expression profiles within minutes following the
surgical excision in coleoctomy specimens and prostatec-
tomy specimens45. Until they are fixed or frozen, biospe-
cimens are viable and capable of reacting to physiological
factors such as changes in temperature, perfusion, oxy-
genation, and other physiological and biochemical vari-
ables, both pre- and intraoperatively, as well as postoper-
atively.
Conclusion
Oncology relies on determining molecular biomarkers
that are involved in disease depiction, prognosis and
treatment. Biomarkers can be grouped into three major
classes: diagnostic, prognostic and predictive ones. Prog-
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nostic and predictive markers, however, may inform on
and predict the course of a disease or malignancy respec-
tively and both should be involved in decision of the
treatment choice. The future of personalized oncology
belongs to clinically useful personalized biomarkers. The
first diagnostic biomarker set (consisting of several sin-
gle biomarkers specific for detecting colorectal and breast
cancer-specific translocations) obtained by whole-geno-
me cancer research using massively parallel sequencing,
identifies residual and recurrent solid tumors with the
sensitivity of detection of mutated DNA present in blood
at levels lower than 0.001%46.
One can expect a growing trend in launching new
drugs with diagnostic markers in order to improve the
treatment outcome of individual patients. This could
therefore shift the focus of healthcare industry from
therapeutics to diagnostics. Unfortunately, at the mo-
ment, pharmaceutical companies are generally more in-
clined to apply whole-genome research in development of
new drugs with improved pharmacology, than to produce
pharmaco-omic tests that might limit the use of their
drugs in the clinic. However, it is obvious that the advan-
tages of personalized molecular oncology are so numer-
ous that the future of cancer research definitely belongs
to it. Being the most reliable cancer-diagnostic disci-
plines, cytology and pathology should participate in this
challenge of deciding about the best therapy for every in-
dividual.
R E F E R E N C E S
1. MASON CE, SERINGHAUS MR, SATTLER DE SOUSA E BRITO
C, Yale J Biol Med, 80 (2007) 145. — 2. WIST AD, BERGER SI, IYENGAR
R, Genome Med, 1 (2009) 11. — 3. JEMAL A, SIEGEL R, WARD E, HAO
Y, XU J, MURRAY T, THUN M, CA Cancer J Clin, 58 (2008) 71. — 4.
JONES S, ZHANG X, PARSONS DW, LIN JC, LEARY RJ, ANGENENDT
P, MANKOO P, CARTER H, KAMIYAMA H, JIMENO A, HONG SM, FU
B, LIN MT, CALHOUN ES, KAMIYAMA M, WALTER K, NIKOLSKAYA
T, NIKOLSKY Y, HARTIGAN J, SMITH DR, HIDALGO M, LEACH SD,
KLEIN AP, JAFFEE EM, GOGGINS M, MAITRA A, IACOBUZIO-
-DONAHUE C, ESHLEMAN JR, KERN SE, HRUBAN RH, KARCHIN
R, PAPADOPOULOS N, PARMIGIANI G, VOGELSTEIN B, VELCU-
LESCU VE, KINZLER KW, Science, 321 (2008) 1801. — 5. SJÖBLOM T,
JONES S, WOOD LD, PARSONS DW, LIN J, BARBER TD, MANDEL-
KER D, LEARY RJ, PTAK J, SILLIMAN N, SZABO S, BUCKHAULTS P,
FARRELL C, MEEH P, MARKOWITZ SD, WILLIS J, DAWSON D,
WILLSON JK, GAZDAR AF, HARTIGAN J, WU L, LIU C, PARMIGIANI
G, PARK BH, BACHMAN KE, PAPADOPOULOS N, VOGELSTEIN B,
KINZLER KW, VELCULESCU VE, Science, 314 (2006) 268. — 6. LEARY
RJ, LIN JC, CUMMINS J, BOCA S, WOOD LD, PARSONS DW, JONES S,
SJÖBLOM T, PARK BH, PARSONS R, WILLIS J, DAWSON D, WILL-
SON JK, NIKOLSKAYA T, NIKOLSKY Y, KOPELOVICH L, PAPADO-
POULOS N, PENNACCHIO LA, WANG TL, MARKOWITZ SD, PARMI-
GIANI G, KINZLER KW, VOGELSTEIN B, VELCULESCU VE, Proc
Natl Acad Sci U S A, 105 (2008) 16224. — 7. WOOD LD, PARSONS DW,
JONES S, LIN J, SJÖBLOM T, LEARY RJ, SHEN D, BOCA SM, BAR-
BER T, PTAK J, SILLIMAN N, SZABO S, DEZSO Z, USTYANKSKY V,
NIKOLSKAYA T, NIKOLSKY Y, KARCHIN R, WILSON PA, KAMINKER
JS, ZHANG Z, CROSHAW R, WILLIS J, DAWSON D, SHIPITSIN M,
WILLSON JK, SUKUMAR S, POLYAK K, PARK BH, PETHIYAGODA
CL, PANT PV, BALLINGER DG, SPARKS AB, HARTIGAN J, SMITH
DR, SUH E, PAPADOPOULOS N, BUCKHAULTS P, MARKOWITZ SD,
PARMIGIANI G, KINZLER KW, VELCULESCU VE, VOGELSTEIN B,
Science, 318 (2007) 1109. — 8. GREENMAN C, STEPHENS P, SMITH R,
DALGLIESH GL, HUNTER C, BIGNELL G, DAVIES H, TEAGUE J,
BUTLER A, STEVENS C, EDKINS S, O’MEARA S, VASTRIK I,
SCHMIDT EE, AVIS T, BARTHORPE S, BHAMRA G, BUCK G,
CHOUDHURY B, CLEMENTS J, COLE J, DICKS E, FORBES S, GRAY
K, HALLIDAY K, HARRISON R, HILLS K, HINTON J, JENKINSON A,
JONES D, MENZIES A, MIRONENKO T, PERRY J, RAINE K, RICH-
ARDSON D, SHEPHERD R, SMALL A, TOFTS C, VARIAN J, WEBB T,
WEST S, WIDAA S, YATES A, CAHILL DP, LOUIS DN, GOLDSTRAW P,
NICHOLSON AG, BRASSEUR F, LOOIJENGA L, WEBER BL, CHIEW
YE, DEFAZIO A, GREAVES MF, GREEN AR, CAMPBELL P, BIRNEY E,
EASTON DF, CHENEVIX-TRENCH G, TAN MH, KHOO SK, TEH BT,
YUEN ST, LEUNG SY, WOOSTER R, FUTREAL PA, STRATTON MR,
Nature, 446 (2007) 153. — 9. MARUSYK A, POLYAK K, Biochim Biophys
Acta, 1805 (2010) 105. — 10. KURAT T, TAMURA K, KANEDA H, NO-
GAMI T, UEJIMA H, ASAI GO G, NAKAGAWA K, FUKUOKA M, Ann
Oncol, 15 (2004) 173. — 11. YANO S, NAKATAKI E, OHTSUKA S, INA-
YAMA M, TOMIMOTO H, EDAKUNI N, KAKIUCHI S, NISHIKUBO N,
MUGURUMA H, SONE S, Oncol Res, 15 (2005) 107. — 12. SHARMA SV,
LEE DY, LI B, QUINLAN MP, TAKAHASHI F, MAHESWARAN S, MC-
DERMOTT U, AZIZIAN N, ZOU L, FISCHBACH MA, WONG KK,
BRANDSTETTER K, WITTNER B, RAMASWAMY S, CLASSON M,
SETTLEMAN J, Cell, 141 (2010) 69. — 13. SHAH SP, MORIN RD,
KHATTRA J, PRENTICE L, PUGH T, BURLEIGH A, DELANEY A,
GELMON K, GULIANY R, SENZ J, STEIDL C, HOLT RA, JONES S,
SUN M, LEUNG G, MOORE R, SEVERSON T, TAYLOR GA,
TESCHENDORFF AE, TSE K, TURASHVILI G, VARHOL R, WARREN
RL, WATSON P, ZHAO Y, CALDAS C, HUNTSMAN D, HIRST M, MAR-
RA MA, APARICIO S, Nature, 461 (2009) 809. — 14. DING L, ELLIS MJ,
LI S, LARSON DE, CHEN K, WALLIS JW, HARRIS CC, MCLELLAN
MD, FULTON RS, FULTON LL, ABBOTT RM, HOOG J, DOOLING DJ,
KOBOLDT DC, SCHMIDT H, KALICKI J, ZHANG Q, CHEN L, LIN L,
WENDL MC, MCMICHAEL JF, MAGRINI VJ, COOK L, MCGRATH SD,
VICKERY TL, APPELBAUM E, DESCHRYVER K, DAVIES S, GUINTO-
LI T, LIN L, CROWDER R, TAO Y, SNIDER JE, SMITH SM, DUKES AF,
SANDERSON GE, POHL CS, DELEHAUNTY KD, FRONICK CC, PAPE
KA, REED JS, ROBINSON JS, HODGES JS, SCHIERDING W, DEES
ND, SHEN D, LOCKE DP, WIECHERT ME, ELDRED JM, PECK JB,
OBERKFELL BJ, LOLOFIE JT, DU F, HAWKINS AE, O’LAUGHLIN
MD, BERNARD KE, CUNNINGHAM M, ELLIOTT G, MASON MD,
THOMPSON DM JR, IVANOVICH JL, GOODFELLOW PJ, PEROU CM,
WEINSTOCK GM, AFT R, WATSON M, LEY TJ, WILSON RK, MARDIS
ER, Nature, 464 (2010) 999. — 15. MINN AJ, KANG Y, SERGANOVA I,
GUPTA GP, GIRI DD, DOUBROVIN M, PONOMAREV V, GERALD WL,
BLASBERG R, MASSAGUÉ J, J Clin Invest, 115 (2005) 44. — 16. MINN
AJ, GUPTA GP, SIEGEL PM, BOS PD, SHU W, GIRI DD, VIALE A,
OLSHEN AB, GERALD WL, MASSAGUÉ J, Nature, 436 (2005) 518. —
17. NGUYEN DX, BOS PD, MASSAGUÉ J, Nat Rev Cancer, 9 (2009) 274.
— 18. SMITH SC, THEODORESCU D, Nat Rev Cancer, 9 (2009) 253. —
19. HUSEMANN Y, GEIGL JB, SCHUBERT F, MUSIANI P, MEYER M,
BURGHART E, FORNI G, EILS R, FEHM T, RIETHMÜLLER G,
KLEIN CA, Cancer Cell, 13 (2008) 58. — 20. PODSYPANINA K, DU YC,
JECHLINGER M, BEVERLY LJ, HAMBARDZUMYAN D, VARMUS H,
Science, 321 (2008) 1841. — 21. CAMPBELL PJ, STEPHENS PJ,
PLEASANCE ED, O’MEARA S, LI H, SANTARIUS T, STEBBINGS LA,
LEROY C, EDKINS S, HARDY C, TEAGUE JW, MENZIES A, GOOD-
HEAD I, TURNER DJ, CLEE CM, QUAIL MA, COX A, BROWN C, DUR-
BIN R, HURLES ME, EDWARDS PA, BIGNELL GR, STRATTON MR,
FUTREAL PA, Nat Genet, 40 (2008) 722. — 22. LEICHMAN CG, LENZ
HJ, LEICHMAN L, DANENBERG K, BARANDA J, GROSHEN S, BOS-
WELL W, METZGER R, TAN M, DANENBERG PV, J Clin Oncol, 15
(1997) 3223. — 23. HEGGIE GD, SOMMADOSSI JP, CROSS DS, HUS-
TER WJ, DIASIO RB, Cancer Res, 47 (1987) 2203. — 24. VAN KUILEN-
BURG AB, MEINSMA R, VAN GENNIP AH, Nucleosides Nucleotides
Nucleic Acids, 23 (2004) 1371. — 25. CSOKA AB, SZYF M, Med Hypothe-
ses, 73 (2009) 770. — 26. DIETRICH J, HAN R, YANG Y, MAYER-PRÖ-
SCHEL M, NOBLE M, J Biol, 5 (2006) 22. — 27. CAGLAR K, VARAN A,
AKYÜZ C, SELEK U, KUTLUK T, YALÇIN B, ATAHAN IL, BÜYÜKPA-
MUKÇU M, J Pediatr Hematol Oncol, 28 (2006) 374. — 28. MARTIN SA,
HEWISH M, LORD CJ, ASHWORTH A, J Pathol, 220 (2010) 281. — 29.
AUFFRAY C, CHEN Z, HOOD L, Genome Med, 1 (2009) 2. — 30. TRE-
VINO V, FALCIANI F, BARRERA-SALDAÑA H, Mol Med, 13 (2007) 527.
— 31. BAUDOT A, GOMEZ-LOPEZ G, VALENCIA A, Genome Biol, 10
(2009) 221. — 32. MATTISON J, VAN DER WEYDEN L, HUBBARD T,
ADAMS DJ, Biochim Biophys Acta, 1796 (2009) 140. — 33. NG SB,
TURNER EH, ROBERTSON PD, FLYGARE SD, BIGHAM AW, LEE C,
S. [tambuk et al.: Personalized Molecular Oncology, Coll. Antropol. 34 (2010) 2: 763–769
768
SHAFFER T, WONG M, BHATTACHARJEE A, EICHLER EE, BAM-
SHAD M, NICKERSON DA, SHENDURE J, Nature, 461 (2010) 272. —
34. CHOI M, SCHOLL UI, JI W, LIU T, TIKHONOVA IR, ZUMBO P, NA-
YIR A, BAKKALOGLU A, OZEN S, SANJAD S, NELSON-WILLIAMS C,
FARHI A, MANE S, LIFTON RP, Proc Natl Acad Sci U S A, 106 (2009)
19096. — 35. PLEASANCE ED, STEPHENS PJ, O’MEARA S, MC-
BRIDE DJ, MEYNERT A, JONES D, LIN ML, BEARE D, LAU KW,
GREENMAN C, VARELA I, NIK-ZAINAL S, DAVIES HR, ORDOÑEZ
GR, MUDIE LJ, LATIMER C, EDKINS S, STEBBINGS L, CHEN L, JIA
M, LEROY C, MARSHALL J, MENZIES A, BUTLER A, TEAGUE JW,
MANGION J, SUN YA, MCLAUGHLIN SF, PECKHAM HE, TSUNG EF,
COSTA GL, LEE CC, MINNA JD, GAZDAR A, BIRNEY E, RHODES
MD, MCKERNAN KJ, STRATTON MR, FUTREAL PA, CAMPBELL PJ,
Nature, 463 (2010) 184. — 36. PLEASANCE ED, CHEETHAM RK, STE-
PHENS PJ, MCBRIDE DJ, HUMPHRAY SJ, GREENMAN CD, VARELA
I, LIN ML, ORDÓÑEZ GR, BIGNELL GR, YE K, ALIPAZ J, BAUER MJ,
BEARE D, BUTLER A, CARTER RJ, CHEN L, COX AJ, EDKINS S,
KOKKO-GONZALES PI, GORMLEY NA, GROCOCK RJ, HAUDEN-
SCHILD CD, HIMS MM, JAMES T, JIA M, KINGSBURY Z, LEROY C,
MARSHALL J, MENZIES A, MUDIE LJ, NING Z, ROYCE T, SCHULZ-
-TRIEGLAFF OB, SPIRIDOU A, STEBBINGS LA, SZAJKOWSKI L,
TEAGUE J, WILLIAMSON D, CHIN L, ROSS MT, CAMPBELL PJ,
BENTLEY DR, FUTREAL PA, STRATTON MR, Nature, 463 (2010) 191.
— 37. ALIZADEH AA, EISEN MB, DAVIS RE, MA C, LOSSOS IS, RO-
SENWALD A, BOLDRICK JC, SABET H, TRAN T, YU X, POWELL JI,
YANG L, MARTI GE, MOORE T, HUDSON J JR, LU L, LEWIS DB,
TIBSHIRANI R, SHERLOCK G, CHAN WC, GREINER TC, WEISEN-
BURGER DD, ARMITAGE JO, WARNKE R, LEVY R, WILSON W, GRE-
VER MR, BYRD JC, BOTSTEIN D, BROWN PO, STAUDT LM, Nature,
403 (2000) 503. — 38. SOTIRIOU C, PUSZTAI L, N Engl J Med, 360
(2009) 790. — 39. MORTAZAVI A, WILLIAMS BA, MCCUE K, SCHAEF-
FER L, WOLD B, Nat Mehods, 5 (2008) 621. — 40. FLUSBERG BA,
WEBSTER DR, LEE JH, TRAVERS KJ, OLIVARES EC, CLARK TA,
KORLACH J, TURNER SW, Nat Methods, 7 (2010) 46. — 41. AZAD NS,
RASOOL N, ANNUNZIATA CM, MINASIAN L, WHITELEY G, KOHN
EC, Mol Cell Proteomics, 5 (2006) 1819. — 42. SANCHEZ-CARBAYO M,
Tumor Biol, 31 (2010) 103. — 43. MARTINKOVA J, GADHER SJ,
HAJDUCH M, KOVAROVA H, FEBS Lett, 583 (2009) 1772. — 44. SREE-
KUMAR A, POISSON LM, RAJENDIRAN TM, KHAN AP, CAO Q, YU J,
LAXMAN B, MEHRA R, LONIGRO RJ, LI Y, NYATI MK, AHSAN A,
KALYANA-SUNDARAM S, HAN B, CAO X, BYUN J, OMENN GS,
GHOSH D, PENNATHUR S, ALEXANDER DC, BERGER A, SHUSTER
JR, WEI JT, VARAMBALLY S, BEECHER C, CHINNAIYAN AM, Nature,
457 (2009) 910. — 45. COMPTON CC, Ann Surg Oncol, 16 (2009) 2079.
— 46. LEARY RJ, KINDE I, DIEHL F, SCHMIDT K, CLOUSER C,
DUNCAN C, ANTIPOVA A, LEE C, MCKERNAN K, DE LA VEGA FM,
KINZLER KW, VOGELSTEIN B, DIAZ LA JR, VELCULESCU VE, Sci
Transl Med, 2 (2010) 20.
S. [tambuk
Split University, University Center for Forensic Sciences, Ru|era Bo{kovi}a 31, 21000 Split, Croatia
e-mail: sstambuk@unist.hr
BUDU]NOST INDIVIDUALNE ONKOLOGIJE
S A @ E T A K
Individualna molekularna medicina pru`a dijagnosti~ke informacije o nastanku i napredovanju bolesti te o njezinom
odgovoru na lijekove na osnovi prou~avanja individualnog molekularnog sadr`aja i njegove strukture. Istovremeno
individualna molekularna farmakologija pru`a informacije o potencijalnim lijekovima i pacijentova odgovoru na njih te
time poti~e ve}u korisnost lijeka izbjegavaju}i njegovu toksi~nost i nedostatak pacijentovog odgovora na lijek. Posto-
janje varijacija u pojedinim genima, posebno onima koji kodiraju za enzime koji metaboliziraju i prenose lijekove ili za
enzime na koje lijekovi djeluju, uvjetuje postojanje razlike me|u individualnim odgovorima na lijekove. Me|utim, veliki
broj bolesti i drugih zdravstvenih stanja, uklju~ivo i razvoj karcinoma, tako|er mogu imati i epigenetsku etiologiju.
Lije~enje karcinoma prioritetno je u individualnom medicinskom istra`ivanju zbog njegove heterogene inter/intraindi-
vidualne prirode uvjetovane postepenom akumulacijom vi{estrukih slu~ajnih ili programiranih mutacija i rearan`mana
kao i epigenetskih promjena, ili uvjetovano stohasti~kim fluktuacijama u sadr`aju stani~nih komponenti. Svi navedeni
faktori u stalnoj su interakciji povratne sprege s tumorskim uvjetima okoli{a i terapije. Prirodna selekcija nadalje obli-
kuje inter/intraindividualnu tumorsku heterogenost putem poticanja klonalne ekspanzije stanica koje sadr`e mutacije
blagotvorne za tumorsku populaciju. Dakle, individualna medicina koja uklju~uje molekularnu medicinu i molekularnu
farmakologiju zasniva se na tretiranju bolesti kod svakog pacijenta na osnovi njegove jedinstvene cjelokupne moleku-
larne strukture (strukture njegova genoma/transkriptoma/RNoma/proteoma/metaboloma/metabonoma) u interakciji s
jedinstvenim uvjetima okoli{a, ~ime se promi~e ideja »odre|eni lijek za odre|enog pacijenta u odre|enoj koli~ini i odre-
|enom vremenu«. Budu}nost bi se individualne onkologije trebala oslanjati na metodama sistemske biologije primije-
njene u citologiji i patologiji, a u svrhu razvoja i kori{tenja efikasnih i djelotvornih dijagnosti~kih, prognosti~kih i pre-
diktivnih biomarkera, {to u kona~nici rezultira pru`anjem molekularnih informacija o nastanku i karakterizaciji
tumora, potencijalu njegova metastaziranja, o adekvatnoj terapiji pa ~ak i o specifi~nim rizicima od {tetnih reakcija na
dane terapije, o tumorskom odgovoru na lijekove, kao i vjerojatnost i njegove remisije.
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